American Journal of Cancer Research and Reviews


Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives

Review Article of American Journal of Cancer Research and Reviews Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives Estrada-Villaseñor E.,1 Meneses A.,2 Valdés-Flores M.,3 Coutiño-Alcaraz JM.,4 Linares-González LM.,5 Olivos Meza A.,6 Ostoa-Saloma P.,7 Delgado Cedillo EA.,8 Landa Solís C.9 1National Institute of Rehabilitation. Pathology Service. Mexico City, México. 2National Cancer Institute. Managing Director. Mexico City, Mexico. 3National Institute of Rehabilitation. Assistant Manager Clinical Research in genetic service. Mexico City, México. 4National Institute of Rehabilitation. Pathology Service. Mexico City, Mexico. 5National Institute of Rehabilitation. Bone Tumors Service. Mexico City, Mexico. 6National Institute of Rehabilitation. Arthroscopy Service. Mexico City, México. 7Postgraduate degree in Biological Sciences, National Autonomous University of Mexico, University City, Mexico, Mexico City. 8National Institute of Rehabilitation. Bone Tumors Service. Mexico City, Mexico. 9National Institute of Rehabilitation. Tissue Engineering and Cell Therapy Unit. Mexico City, Mexico. Giant cell tumor of bone (GCTB) is a primary bone tumor, locally aggressive. For many, a GCTB is considered a tumor with an unpredictable behavior, particularly regarding recurrences, pulmonary implants, and the possibility of primary malignancy. In terms of risk of recurrence, it is known that it is associated with the type of treatment used initially for the GCTB. The greater the number or recurrences, the greater the risk of pulmonary implants, and the greater the risk of malignant degeneration. Therefore, much of the prognosis of this tumor could be related to the type of initial treatment. Hence the importance of the treatment theme. This review includes a comparison between the various modalities for treatment in GCTB, considering the advantages and disadvantages of each one. Existing GCTB treatments are not 100% safe and effective at the same time. and this is the reason why the search for other treatment modalities should continue to offer a better oncologic and functional outcome to ...

Application of Artificial Intelligence in Breast Medical Imaging Diagnosis

Review Article of American Journal of Cancer Research and Reviews Application of Artificial Intelligence in Breast Medical Imaging Diagnosis Yao Xiao1*, Yiyuan Qu1, Tingting Wu1 1College of Medicine, China Three Gorges University, Yichang, 443002, China. According to the latest report on urban cancer in China published in 2017: China is one of the countries with the fastest growing incidence of breast cancer, and the age of onset has gradually become younger. Newly diagnosed breast cancer patients in China account for 12.2% of new breast cancer patients worldwide, and the mortality rate is 9.6%. A large amount of clinical experience has proven that the survival rate of breast cancer detected at an early stage is significantly higher than that detected at an advanced stage. Imaging examination is an important method for early detection of breast cancer. With the advent of the Artificial Intelligent, the method of AI + medical imaging has been widely used in lungs, breasts, heart, skull, liver, prostate, bones and other parts. Methods used in breast cancer screening include: breast self-examination and clinical physical examination, mammography of mammography of the breast, ultrasound of the breast, and magnetic resonance imaging (MRI) of the breast. The advantages and disadvantages have been reflected in the development and application in recent years. This article will review the advantages and disadvantages of combined diagnosis of AI and breast medicine. It is hoped that the artificial intelligence of medical imaging screening for breast diseases has a brighter and broader prospect. Keywords: Breast; Medical imaging; Artificial intelligence (AI); Advantages and disadvantages ...

Review on breast cancer immunotherapy

Review Article of American Journal of Cancer Research and Reviews Review on breast cancer immunotherapy Selamawit Fentahun Ali School of Veterinary Medicine, Wollo University Cancer immunotherapy consists of approaches that modify the host immune system, and/or the utilization of components of the immune system for treatment and prevention of cancer. Eventhough breast cancer has historically not been considered a favorable target for immunotherapies as compared to those solid tumors such as melanoma and renal cell carcinoma, several preclinical and clinical studies have provided important insights and clinical data that support its potential to improve clinical outcomes for patients with breast cancer. In addition, the recent definition of tumor-specific immunity in breast cancer patients and the identification of several breast cancer antigens has generated enthusiasm for the application of immune based therapies to the treatment of breast malignancies. In general, immunotherapies can be considered either non-specific, such as cytokine, or tumor specific for example a vaccine that targets breast cancer tumor antigens. Current immunotherapeutic approaches either through immunization of the patient (e.g., by administering a cancer vaccine), in which case the patient’s own immune system is trained to recognize tumor cells as targets to be destroyed, or through the administration of therapeutic antibodies as drugs, in which case the patient’s immune system is recruited to destroy tumor cells by the therapeutic antibodies, Cell based immunotherapy is another major entity of cancer immunotherapy. The review concluded that immunotherapeutic approaches combined with novel sequences of chemotherapies, radiation, and immunomodulating agents hold promise for enhancing the treatment of breast cancer. Keywords: immunotherapy, monoclonal antibodies, cytokine, breast cancer, immune system and cancer vaccines ...

Research progress of cervical cancer

Review Article of American Journal of Cancer Research and Reviews Research progress of cervical cancer Xizi Yan1*, Lijuan Li1, Qian Zhang2, Chengming Yang3 1College of Medicine, China Three Gorges University, Yichang, 443002, China. 2College of Arts & Communication, China Three Gorges University, Yichang, 443002, China. 3College of Hydraulic & Environmental Engineering, China Three Gorges University, Yichang 443002 Cervical cancer is a common malignant tumor of the female reproductive system. Its incidence is second only to breast cancer, and it is gradually becoming younger. Because it has great harm to women’s physical and mental health, and its related research has been the focus of public attention, we decided to conduct research on the pathogenesis, prevention and intervention, detection methods, treatment methods, and postoperative effects of cervical cancer Summary discussion. Keywords:Cervical cancer; Pathogenesis preventive intervention; Testing method; Treatment method ...

Dr. Elsayed Ibrahim Elagamy
Professor of Immunology, Department of Applied Medical Sciences, College of Community (Unaizah), Qassim University, Kingdom of Saudi Arabia.

Dr. Indrasena R Kummetha
University of California San Diego (UCSD), Department of Pediatrics, 9500 Gilman Drive, MC 0762, BRF-11, Room NO:2220, San Diego, California, 92093, USA

Dr. Zhiqiang Hou
Senior Research Associate, Center for Alzheimer’s and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX 75390

Dr. Nisar Haider Zaidi
MBBS, MS, MRCS (Glasgow), FICS, FACS. Department of surgery, King Abdulaziz University Hospital , POBox-80215 Jeddah 21589 , Saudi Arabia

Dr. Shahin Gavanji
Chairman of “WAMS National Council of Iran at World Academy of Medical Sciences (WAMS), Chairman WAMS Oncology Research Group of Iran, Young Researchers and Elite Club, Khorasgan Branch, Islamic Azad University, Khorasgan, Isfahan, Iran, Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran.

Dr. Kabita Mishra
D.D.P.R.-Central Research Institute for Homoeopathy , (Ministry of A.Y.U.S.H., Government of India)

Dr. Prakash Prajapat
Assistant Professor, Department of Chemistry, Mehsana Urban Institute of Sciences, Ganpat University

Dr. Naoshad Muhammad
Department of Radiation Oncology, School of Medicine, Washington University in Saint Louis

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1.ZAICHICK Vladimir and ZAICHICK Sofia. Trace Element Contents in Thyroid Cancer Investigated by Energy Dispersive X-Ray Fluorescent Analysis. American Journal of Cancer Research and Reviews, 2018,2:5. DOI: 10.28933/ajocrr-2017-12-2801 
2.Kénémé Bineta; Ciss Daouda; Ka Sidy; Mbaye Fatimata; Dem Ahmadou; Sembène Mbacké. UTERINE FIBROIDS IN SENEGAL: POLYMORPHISM OF MED12 GENE AND CORRELATION WITH EPIDEMIOLOGICAL FACTORS. American Journal of Cancer Research and Reviews, 2018,2:4. DOI:10.28933/ajocrr-2017-12-2601 

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access

The American Journal of Cancer Research and Reviews is a peer reviewed open access journal publishing research manuscripts, review articles, case reports, editorials, letters to the editor in Cancer Research and Reviews (indexing details).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions soon.

American Journal of Cancer Research and Reviews

Loading